PMID- 32349103
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1539-2864 (Electronic)
IS  - 0275-004X (Linking)
VI  - 41
IP  - 2
DP  - 2021 Feb 1
TI  - SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FEATURES OF VITREORETINAL LYMPHOMA 
      IN 55 EYES.
PG  - 249-258
LID - 10.1097/IAE.0000000000002819 [doi]
AB  - PURPOSE: To evaluate spectral domain optical coherence tomography (SD-OCT) 
      features of vitreoretinal lymphoma (VRL). METHODS: Review of records and SD-OCT 
      images of vitreoretinal lymphoma evaluated at Ocular Oncology Service, Wills Eye 
      Hospital between July 1, 2000, and April 1, 2019. RESULTS: There were 55 eyes of 
      32 patients included. At presentation, SD-OCT features included vitreous 
      opacities (n = 36, 65%), preretinal deposits (n = 7, 13%), intraretinal deposits 
      (n = 8, 15%), subretinal deposits (n = 20, 36%), retinal pigment epithelium 
      abnormalities (n = 35, 64%), and subretinal pigment epithelium deposits (n = 35, 
      64%). Of 36 eyes with observed tumor progression, comparison (initial visit vs. 
      time of progression) revealed more intraretinal deposits (17% vs. 50%, P = 0.005) 
      at progression. Of 15 eyes with tumor recurrence, comparison (initial visit vs. 
      time of recurrence) revealed more intraretinal deposits (7% vs. 47%, P = 0.04) at 
      recurrence. At last visit, 39 eyes demonstrated tumor regression. By comparison 
      (initial presentation vs. regression), there were less frequent vitreous 
      opacities (67% vs. 0%, P < 0.001), intraretinal deposits (15% vs. 0%, P = 0.03), 
      subretinal deposits (36% vs. 0%, P < 0.001), and subretinal pigment epithelium 
      deposits (69% vs. 21%, P < 0.001) at regression. CONCLUSION: Using SD-OCT in 
      patients with vitreoretinal lymphoma, local tumor regression correlated with a 
      reduction in vitreous opacities, intraretinal deposits, subretinal deposits, and 
      subretinal pigment epithelium deposits. SD-OCT is useful in judging vitreoretinal 
      lymphoma response to therapy.
FAU - Yang, Xiaolu
AU  - Yang X
AD  - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 
      Philadelphia, Pennsylvania.
AD  - Department of Ophthalmology, Shanghai General Hospital, Shanghai, China; and.
FAU - Dalvin, Lauren A
AU  - Dalvin LA
AD  - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 
      Philadelphia, Pennsylvania.
AD  - Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.
FAU - Mazloumi, Mehdi
AU  - Mazloumi M
AD  - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 
      Philadelphia, Pennsylvania.
FAU - Ferenczy, Sandor
AU  - Ferenczy S
AD  - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 
      Philadelphia, Pennsylvania.
FAU - Lim, Li-Anne S
AU  - Lim LS
AD  - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 
      Philadelphia, Pennsylvania.
FAU - Ancona-Lezama, David
AU  - Ancona-Lezama D
AD  - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 
      Philadelphia, Pennsylvania.
FAU - Shields, Jerry A
AU  - Shields JA
AD  - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 
      Philadelphia, Pennsylvania.
FAU - Mashayekhi, Arman
AU  - Mashayekhi A
AD  - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 
      Philadelphia, Pennsylvania.
FAU - Shields, Carol L
AU  - Shields CL
AD  - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 
      Philadelphia, Pennsylvania.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Retina
JT  - Retina (Philadelphia, Pa.)
JID - 8309919
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Fluorescein Angiography/methods
MH  - Follow-Up Studies
MH  - Fundus Oculi
MH  - Humans
MH  - Lymphoma/*pathology
MH  - Male
MH  - Middle Aged
MH  - Retinal Neoplasms/*pathology
MH  - Retinal Pigment Epithelium/*pathology
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence/*methods
MH  - Vitreous Body/*pathology
EDAT- 2020/04/30 06:00
MHDA- 2021/09/15 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 00006982-202102000-00003 [pii]
AID - 10.1097/IAE.0000000000002819 [doi]
PST - ppublish
SO  - Retina. 2021 Feb 1;41(2):249-258. doi: 10.1097/IAE.0000000000002819.